Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
A single patient remains disease-free after a new chemo-immunotherapy approach for rare breast cancer
This case report describes a 71-year-old woman with triple-negative neuroendocrine breast cancer treated with paclitaxel, cisplatin, and pem…
A 71-year-old woman with rare breast cancer stayed disease-free for a year using a combination of chemotherapy and immunotherapy that doctor…
Gut microbiome factors and dietary modulation may optimize triple-negative breast cancer management
Gut bacteria and diet may hold new keys for triple-negative breast cancer care
This narrative review examines the role of gut microbiome composition, antibiotics, obesity, and dietary modulation in triple-negative breas…
A review explores how gut bacteria, antibiotics, and diet could change treatment for triple-negative breast cancer patients.
Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
Docetaxel chemotherapy linked to rare heart attack in breast cancer patient
This case report and literature review examines acute myocardial infarction following docetaxel chemotherapy in a patient with triple-negati…
A rare heart attack occurred after docetaxel chemotherapy in a patient with triple-negative breast cancer. This case review suggests the dru…
Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
A Hidden Protein in Aggressive Breast Cancer May Unlock New Treatments
This meta-analysis of 12 studies in 1,545 TNBC patients found a pooled NY-ESO-1 expression prevalence of 16.1%. The authors note substantial…
A protein found in about one in six triple-negative breast cancers could open the door to immune-based treatments that target cancer cells w…
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
Adding immune drugs to chemo helps early stage triple negative breast cancer patients stay disease free longer
A meta-analysis found neoadjuvant immune checkpoint inhibitors with chemotherapy significantly improved event-free survival but not overall …
A large review of trials found that adding immune checkpoint inhibitors to chemotherapy improves survival chances for early stage triple neg…
Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
New drug combo did not extend life for metastatic triple-negative breast cancer patients in this trial
This phase III RCT in 812 patients with previously untreated metastatic triple-negative breast cancer found that adding capivasertib to pacl…
A large global trial found that adding capivasertib to paclitaxel did not improve overall survival for patients with metastatic triple-negat…
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
AI-mediated ultrasonic radiomics shows potential for triple-negative breast cancer diagnosis and prognosis
AI tools show promise for triple negative breast cancer
This review of research progress examines AI-mediated ultrasonic radiomics for patients with triple-negative breast cancer (TNBC).
New AI methods using ultrasound images may help doctors better identify and predict how triple negative breast cancer might progress.
Review of immunotherapy innovations for triple-negative breast cancer survival
New Hope for Tough-to-Treat Breast Cancer
This narrative review examines immunotherapy innovations, including immune checkpoint inhibitors and combination strategies, for patients wi…
This approach may change how doctors treat one of the hardest forms of breast cancer.
Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients
New Drug Combo Stops Breast Cancer Growth
This Phase 1 study enrolled 34 evaluable patients with previously treated triple-negative, hormone-resistant, or HER2-negative metastatic br…
This new combination may help some patients keep their cancer stable for months when other options have run out.
Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms
Why Some BRCA Breast Cancers Shrug Off Talazoparib Before Surgery
This Phase II neoadjuvant trial evaluated talazoparib in patients with germline mutant breast tumors.
Some BRCA breast cancers shrink under talazoparib, but others find hidden escape routes that let them ignore the drug before surgery.
Research across Hormone Receptor-Positive Breast Cancer
Related studies from across the Hormone Receptor-Positive Breast Cancer family.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
Fulvestrant maintenance therapy significantly improves progression free survival compared to capecitabine in hormone receptor positive metastatic breast cancer patients
This randomized phase 3 trial in 210 patients with HR+ HER2- metastatic breast cancer compared fulvestrant to capecitabine after first-line …
In a study of 210 patients in China, fulvestrant helped keep cancer from growing longer than capecitabine. Fewer serious side effects occurr…
Radiofrequency ablation followed by radiation therapy shows noninferior 5-year recurrence-free survival compared to partial mastectomy in early stage breast cancer
Radiofrequency Ablation Offers Breast Cancer Patients a Less Invasive Option
This Phase 3 multicenter study evaluated 370 female patients with early stage breast cancer (Tis-T1, N0M0). Radiofrequency ablation followed…
A new five-year study proves that a needle-based treatment works just as well as removing part of the breast for early stage cancer.
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.
Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer
New Drug Combo Slashes Breast Cancer Progression Risk by 75%
This phase III randomized trial evaluated gedatolisib plus fulvestrant with or without palbociclib in patients with hormone receptor-positiv…
For patients with tough-to-treat advanced breast cancer, a new three-drug combination nearly quadrupled the time before the cancer started g…
Meta-analysis finds oral SERDs improve PFS over standard ET in HR+ HER2- ABC
New Drug Helps Some Breast Cancer Patients Live Longer
This systematic review and meta-analysis of 2,808 patients with HR+ HER2- advanced breast cancer found oral SERDs improved progression-free …
New oral pills help some advanced breast cancer patients live longer and fight back against drug resistance by blocking estrogen growth sign…
Adherence to 2021 ABS imaging recommendations in 148 male breast referrals at a UK hospital
Why Most Lumps in Men Don't Need a Mammogram, but Many Still Get One
This retrospective observational cohort study evaluated adherence to 2021 ABS imaging recommendations among 148 male patients referred to a …
A year-long UK clinic review found that most men referred for breast lumps had benign conditions, yet imaging was often done despite nationa…
Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer
New Test Predicts Who Needs Chemo in Breast Cancer
This randomized phase II trial evaluated sequential administration of paclitaxel and palbociclib with endocrine therapy in patients with ER+…
Doctors now have a way to spot patients who can skip chemo and go straight to safer hormone treatment.
Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles
New analysis suggests specific chemo schedules may improve outcomes for early breast cancer patients
This network meta-analysis evaluated Phase II and Phase III trials involving 17,187 women with early-stage breast cancer receiving adjuvant…
A new analysis of 17,187 women with early breast cancer suggests specific chemo schedules may improve outcomes and reduce side effects.
Questions about Triple-Negative Breast Cancer
What are the new treatments for triple-negative and HER2-positive Breast Cancer?
New treatments for triple-negative breast cancer include chemo-immunotherapy (pembrolizumab plus platinum-based chemo) and potential NY-ESO-1 targeted therapies; for HER2-positive breast cancer, neoadjuvant targeted combinations and post-neoadjuvant trastuzumab emtansine are key
Full answer →Did the atezolizumab trial show better progression-free survival for metastatic triple-negative breast cancer patients?
Yes, the IMpassion130 trial showed atezolizumab plus nab-paclitaxel improved progression-free survival in PD-L1-positive metastatic triple-negative breast cancer, leading to FDA approval.
Full answer →Does taking capecitabine or trastuzumab emtansine treat triple-negative breast cancer effectively?
Capecitabine is not a standard treatment for triple-negative breast cancer (TNBC); trastuzumab emtansine targets HER2-positive cancer, not TNBC. Neither is considered effective for TNBC.
Full answer →What are the new immunotherapy options available to improve survival for triple-negative breast cancer patients?
New immunotherapy options for triple-negative breast cancer include immune checkpoint inhibitors like pembrolizumab combined with chemotherapy, which improve survival in PD-L1-positive advanced disease and early-stage patients.
Full answer →Does adding immune checkpoint inhibitors to chemotherapy improve survival for early-stage triple-negative breast cancer?
Yes, adding immune checkpoint inhibitors (like pembrolizumab) to chemotherapy improves event-free survival and pathologic complete response in early-stage triple-negative breast cancer, with some trials also showing overall survival benefit.
Full answer →All Triple-Negative Breast Cancer Articles
- Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
- Gut microbiome factors and dietary modulation may optimize triple-negative breast cancer management
- Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
- Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
- Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
- Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
- Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
- Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
- AI-mediated ultrasonic radiomics shows potential for triple-negative breast cancer diagnosis and prognosis
- Review of immunotherapy innovations for triple-negative breast cancer survival
- Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients
- Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms
- Meta-analysis finds immunotherapy plus chemotherapy improves outcomes in triple-negative breast cancer
- Pyroptosis-related gene signature predicts prognosis in triple-negative breast cancer patients
- Neoadjuvant chemotherapy plus sintilimab improved response rates versus chemotherapy alone in 61 patients with triple-negative breast cancer
- Atezolizumab plus chemotherapy improved progression-free survival and patient-reported quality of life in metastatic triple-negative breast cancer
- PSMA PET/CT shows uptake in half of metastatic triple-negative breast cancer patients